This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page


    Page   1/1   
  • In the face of uncertainty: A challenging future for biopharmaceutical innovation
    The biopharmaceutical industry is in a precarious position regarding innovation: big bets in bold new areas are fraught with complexity and uncertainty, while success in mature therapeutic areas is becoming increasingly challenging.
  • The scientific information landscape and applications to translational research
    Investments made in biomedical and translational research have led to advancements in providing insights into the mechanisms and disease relevant markers that are implicated in human pathologies.
  • 2013 Global life sciences outlook: Optimism tempered by reality in a “new normal”
    Following years of growth and favourable market trends, the global life sciences industry now finds itself facing a challenging "new normal."
  • Biopharma Customer Facing Model v2.0
    Health care treatment decisions are increasingly influenced by dynamic groups of local health stakeholders — what Deloitte refers to as health ecosystems.
  • The case for change
    The health care landscape is expected to evolve over the next decade. Find out about how changes will affect multiple stakeholders, including providers, health plans, employers, state governments, and biopharma companies.
  • Choices and Capabilities for Life Sciences Companies
    This article explores important choices and capabilities this changing environment demands from life sciences companies as well as tough, specific questions to challenge an organisation’s approach to reform.
  • Commercial capability outsourcing: A significant risk to the industry?
    The pharmaceutical industry has historically maintained direct control over core business activities. However, over time, there is an increasing willingness to outsource value chain activities within the heart of the business.
  • Page   1/1   
Stay connected:
More on Deloitte
Learn about our site